<DOC>
	<DOCNO>NCT00800137</DOCNO>
	<brief_summary>Many cardiac patient require device ( defibrillator pacemaker ) relate surgery chronic oral anticoagulation therapy ( usually coumadin ) . The risk blood clot formation relate stop oral anti-coagulant therapy currently manage use bridge heparin therapy patient moderate high risk blood clot formation . There substantial risk bleed pocket device situate ( pocket hematoma ) relate bridge therapy . The purpose study compare current standard care bridge heparin experimental strategy continue coumadin therapy high risk patient undergoing device surgery , hypothesis continue oral anti-coagulation group lower pocket hematoma rate compare bridge heparin group .</brief_summary>
	<brief_title>Bridge Continue Coumadin Device Surgery Randomized Controlled Trial</brief_title>
	<detailed_description>Eligible patient equally randomize ( 1:1 ) Conventional/control arm ( bridge anti-coagulation ) Experimental arm ( continued coumadin ) . In Conventional arm 2 option . Patients great 5 day pre-implant discontinue oral anti-coagulant ( coumadin ) 5 day procedure , start full therapeutic dos subcutaneous low molecular weight heparin ( LMWH ) 3 day procedure . Patients less 5 day implant give Vitamin K investigator 's discretion start full therapeutic dos either subcutaneous LMWH IV unfractionated Heparin ( choice investigator discretion ) INR therapeutic range patient ( usually great equal 2 ; 2.5 valve patient ) surgery proceed INR less 1.6 . Oral anti-coagulant ( coumadin ) resume even procedure . Full dose LMWH injection full dose IV heparin start 24 hour surgery . In Experimental arm patient continue oral anti-coagulant ( coumadin ) . The INR day surgery &lt; 3.0 . ASA continue patient . Plavix continue patient drug-eluting stent . Patients monitor development hematoma bleed event admission . There unblinded team responsible device implant follow-up blind team responsible monitor bleed event hematoma determine meet primary endpoint criterion study . The blinded team knowledge treatment arm involve patient develops hematoma bleed event . All hematomas bleed event follow resolution .</detailed_description>
	<mesh_term>Hematoma</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Any patient undergoing elective device surgery ( i.e . de novo device implantation pulse generator change lead replacement pocket revision ) 2 . Patient moderate high risk arterial thromboembolic event ( ATE ) high risk venous thromboembolic event ( VTE ) ( define one follow ) : Prosthetic mitral valve replacement Caged ball tilt disc aortic valve prosthesis Bileaflet aortic valve prosthesis one : AF ( atrial Fibrillation/Atrial Flutter ) , prior stroke TIA , hypertension , diabetes , CHF age &gt; 75 AFib/Flutter associate rheumatic valvular heart disease Nonrheumatic AFib/Flutter CHADS2 risk criterion SCORE &gt; 2 Nonrheumatic AFib/Flutter stroke TIA ( within 3 month ) Persistent/permanent AFib/Flutter day acceptance device surgery AND plan cardioversion DFT test device implant Recent ( within 3 month ) VTE Severe thrombophilia ( Protein C S deficiency antithrombin antiphospholipid antibody multiple abnormality ) 3 . Willing selfinject relative friend nurse inject LMWH 1 . Unable ro unwilling provide inform consent 2 . History noncompliance medical therapy 3 . Renal failure Cr &gt; 180 umol/l 4 . Prior Heparin induce thrombocytopenia 5 . Active device infection</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>coumadin</keyword>
	<keyword>device surgery</keyword>
	<keyword>pocket hematoma</keyword>
	<keyword>Pocket hematoma device surgery</keyword>
</DOC>